A Business Case to Standardize EDC Across Study Phases

Jul 20, 2026 | Jon Young

When launching a new clinical trial, it is easy to fall into the habit of evaluating electronic data capture (EDC) systems on a transactional, study-by-study basis. Selecting a lightweight system optimized strictly for speed and cost might satisfy your immediate needs for an early-phase trial. But this piecemeal approach creates a fragmented technical foundation as your company grows, leaving you with a patchwork of disconnected tools and processes across different phases.

The reality is that changing your technology platform becomes significantly harder and more disruptive as your biotech company and its pipeline mature. Instead of waiting until your pipeline expands, establish deep technical roots before scaling. Standardizing on the right EDC platform across all clinical phases and studies – rather than switching tools based on early phase needs – reduces long-term complexity, lowers your total cost of ownership (TCO), and effectively prepares your biotech for sustainable growth.

The cost of fragmented systems

While this study-by-study approach might seem practical, it introduces hidden inefficiencies across your portfolio. Instead of building momentum, clinical teams lose valuable time starting from scratch for every single study because they lack a base standards library to build from.

This technical fragmentation quickly trickles down into everyday operations. Inconsistency across phases leads to disjointed downstream systems and data integrations. Critical data governance is often overlooked until data issues emerge late in the pipeline. Ultimately, the constant state of change management forces teams to waste resources on recurring vendor contracts, distinct system validations, and repetitive user training.

How a small biotech standardized for long-term scale

Benefits of broad EDC standardization

By standardizing EDC early, your data management team can begin contributing to a global standards library from day one. Instead of rebuilding the wheel for every trial, this foundational setup reduces the configuration and build effort required for all subsequent studies. Because most EDCs share similar core functionality, user preference among site staff and CRAs is heavily driven by familiarity. Keeping the same system across phases provides a consistent user experience. This is especially crucial for early-phase oncology trials where investigative sites are managing actual patients rather than healthy volunteers.

Beyond day-to-day usability, broad standardization improves your inspection readiness and financial efficiency. Having a single, unbroken audit trail across all clinical phases makes it much easier for your team to speak confidently to regulators during inspections. This approach also delivers a much lower TCO. By eliminating the operational drag of managing multiple software vendors, executing completely separate system validations, and maintaining scattered integrations, emerging biopharmas can protect both their timelines and their budgets.

Looking beyond the next study

Even if your company’s long-term vision isn’t fully certain, or if a phase II program is still three years away, planning for EDC standardization pays off unless your immediate strategy is to sell off the asset. Taking a short-term view of clinical technology only creates compounding technical debt. Emerging biopharmas do not need to navigate this journey alone. A comprehensive system like Veeva EDC provides the necessary speed and affordability upfront, while offering a clear offramp to transition complete data ownership back to the sponsor over time as your internal team and expertise grow.

Watch the demo to see how Veeva EDC can streamline your data management processes.